Borrelia burgdorferi Johnson et al. emend. Baranton et al. (ATCC® 53899)

Strain Designations: 297  /  Type Strain: no  /  Biosafety Level: 2

Strain Designations 297
Application
Assay for antibodies
Emerging infectious disease research
Vector borne research
Isolation
Cerebrospinal fluid
Biosafety Level 2

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Product Format frozen
Storage Conditions Frozen: -80°C or colder
Freeze-Dried: 2°C to 8°C
Live Culture: See Propagation Section
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
Preceptrol® no
Type Strain no
Comments
Lyme disease
Medium ATCC® Medium 1914: Revised BSK medium
ATCC® Medium 260: Trypticase soy agar/broth with defibrinated sheep blood
Growth Conditions
Temperature: 35°C to 37°C
Atmosphere: Aerobic
Name of Depositor Gundersen Medical Foundation
U.S. Patent Number
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
Chain of Custody
ATCC <-- Gundersen Medical Foundation <-- A.C. Steere
Isolation
Cerebrospinal fluid
References

Steere AC, et al. The spirochetal etiology of Lyme disease. N. Engl. J. Med. 308: 733-740, 1983. PubMed: 6828118

Western Blot Assay for Antibodies to Borrelia burgdorferi; Approved Guideline. Wayne, PA. Clinical and Laboratory Standards Institute; CLSI M34-A.